Dose scheduling and pharmacokinetic (PK) study of trastuzumab in patients (pts) with HER2/neu overexpressing breast cancer?A. Felici, F. Cognetti, M. Contestabile et al.|Journal of Clinical Oncology|2007Cited by 3